Eisai and Biogen’s subcutaneous Leqembi set for FDA review
Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi …
Post
-
-
Normunity raises $75m to advance solid tumour targeting T-cell engagers
US-based Normunity has raised $75m in a Series B funding round to support the clinical development of its lead programme, …
-
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be key to entering the obesity market. Presenting at …
-
Enhancing patient engagement and outcomes in the NHS
Medication non-adherence is an enduring issue in the UK healthcare system, costing the NHS a staggering £930 million annually.[i] Despite …
-
Pharmaceutical Technology Excellence Awards 2024: Syngene
Syngene International is a leading integrated contract research, development, and manufacturing organization (CRDMO). The company was honored with three awards …
-
Pharmaceutical Technology Excellence Awards 2024: IFF Pharma Solutions
IFF Pharma Solutions has been recognized for its marketing strategies and leadership in controlled release technologies, earning the Marketing Award …
-
Pharmaceutical Technology Excellence Awards 2024: Image Analysis Group
IImage Analysis Group (IAG) has won an award in the Innovation category in the 2024 Pharmaceutical Technology Excellence Awards for …
-
Eli Lilly targets Scorpion Therapeutics to expand reach in oncology
Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away …
-
Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025
Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues …
-
Biogen proposes acquisition of partner Sage Therapeutics
Biogen has made an unsolicited offer to acquire its partner Sage Therapeutics following a year of significant challenges for the …
-
Gilead and LEO Pharma link on programmes for inflammatory conditions
Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small …
-
JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic
In moves that continue to strengthen its affiliation with the healthcare industry, NVIDIA has added three new companies to its …
-
Small matter, big challenges: Nano milling in a sterilised environment
Nano milling involves transforming hydrophobic APIs into a water-soluble form and is achieved by reducing the API down in size …
-
Update: Johnson & Johnson acquires Intra-Cellular Therapies
Johnson & Johnson (J&J) has announced it will acquire Intra-Cellular Therapies, a company specialising in central nervous system disorder treatments. The …
-
JP Morgan 2025: GSK acquires IDRx in $1.15bn deal
GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for …
